Sign In
Buy FLGT
$18.14
-0.560 (-2.99%)
At Close: Jun 03, 2026
Fulgent Genetics: Core Growth Re-Acceleration Will Be The Critical Catalyst
12:05pm, Monday, 09'th Sep 2024
Fulgent Genetics' core revenue grew just 3% in H1 2024, with full-year guidance of $280 million implying a step-up to 11% growth in H2 and 7% for FY 2024. Growth in precision diagnostics (+35% in H1 2
Fulgent Genetics (FLGT) Upgraded to Buy: What Does It Mean for the Stock?
01:00pm, Tuesday, 13'th Aug 2024
Fulgent Genetics (FLGT) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
How Much Upside is Left in Fulgent Genetics (FLGT)? Wall Street Analysts Think 27.22%
10:55am, Tuesday, 13'th Aug 2024
The mean of analysts' price targets for Fulgent Genetics (FLGT) points to a 27.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among
Fulgent Genetics, Inc. (FLGT) Beats Q2 Earnings and Revenue Estimates
09:17am, Friday, 02'nd Aug 2024
Fulgent Genetics, Inc. (FLGT) came out with quarterly earnings of $0.15 per share, beating the Zacks Consensus Estimate of a loss of $0.31 per share. This compares to loss of $0.08 per share a year ag
Fulgent Reports Second Quarter 2024 Financial Results
07:00am, Friday, 02'nd Aug 2024
EL MONTE, Calif.--(BUSINESS WIRE)--Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent,” or the “Company”), a technology-based company with a well-established laboratory services business and a th
Fulgent Genetics (FLGT) Soars 6.6%: Is Further Upside Left in the Stock?
05:41am, Thursday, 18'th Jul 2024
Fulgent Genetics (FLGT) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength dow
PRESS RELEASE - 10/06/2024, 07:00 CEST Biocartis Welcomes Gina Wallar, PhD as Chief Business Officer and Judith Vacchino, PhD as VP Global Marketing Mechelen, Belgium 10 June 2024 – Biocartis NV (
EL MONTE, Calif.--(BUSINESS WIRE)--Fulgent Pharma, a subsidiary of Fulgent Genetics, Inc. (NASDAQ: FLGT) and a leading nanobiotechnology company specializing in innovative cancer therapeutics, today a
EL MONTE, Calif.--(BUSINESS WIRE)--Fulgent Pharma, a subsidiary of Fulgent Genetics, Inc. (NASDAQ: FLGT) and a leading nanobiotechnology company specializing in innovative cancer therapeutics, today a
Moffitt Cancer Center and Fulgent Pharma Join Forces to Revolutionize Cancer Therapeutics
04:05pm, Tuesday, 14'th May 2024
TAMPA, Fla. & LOS ANGELES--(BUSINESS WIRE)--Moffitt Cancer Center, a world-renowned cancer treatment and research center, and Fulgent Pharma, a subsidiary of Fulgent Genetics, Inc. (NASDAQ: FLGT) and
Fulgent Genetics, Inc. (FLGT) Reports Q1 Loss, Misses Revenue Estimates
09:16am, Friday, 03'rd May 2024
Fulgent Genetics, Inc. (FLGT) came out with a quarterly loss of $0.01 per share versus the Zacks Consensus Estimate of a loss of $0.33. This compares to loss of $0.22 per share a year ago.
Fulgent Reports First Quarter 2024 Financial Results
07:00am, Friday, 03'rd May 2024
EL MONTE, Calif.--(BUSINESS WIRE)--Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent,” or the “Company”), a technology-based company with a well-established laboratory services business and a th
Fulgent Genetics to Announce First Quarter 2024 Financial Results on Friday, May 3, 2024
04:05pm, Thursday, 11'th Apr 2024
EL MONTE, Calif.--(BUSINESS WIRE)--Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent” or the “Company”), a technology-based company with a well-established laboratory services business and a the
Fulgent Genetics (FLGT) Q4 2023 Earnings Call Transcript
10:59am, Wednesday, 28'th Feb 2024
Fulgent Genetics (FLGT) Q4 2023 Earnings Call Transcript
Fulgent Reports Fourth Quarter and Full Year 2023 Financial Results
07:00am, Wednesday, 28'th Feb 2024
EL MONTE, Calif.--(BUSINESS WIRE)--Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent,” or the “Company”), a technology-based company with a well-established laboratory services business and a th
